Comparative Pharmacology
Head-to-head clinical analysis: ALLOPURINOL versus ALOPRIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALLOPURINOL versus ALOPRIM.
ALLOPURINOL vs ALOPRIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Allopurinol inhibits xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and xanthine to uric acid, thereby reducing serum and urinary uric acid concentrations. It also inhibits de novo purine synthesis through feedback inhibition.
Allopurinol inhibits xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and xanthine to uric acid, thereby reducing serum and urinary uric acid concentrations.
100-600 mg orally once daily; initial 100 mg/day with weekly increases of 100 mg/day; maximum 800 mg/day.
300 mg orally once daily; may be increased to 600-800 mg/day in divided doses for severe gout.
None Documented
None Documented
Clinical Note
moderateAllopurinol + Hydrochlorothiazide
"The risk of a hypersensitivity reaction to Hydrochlorothiazide is increased when it is combined with Allopurinol."
Clinical Note
moderateAllopurinol + Bendroflumethiazide
"The risk of a hypersensitivity reaction to Bendroflumethiazide is increased when it is combined with Allopurinol."
Clinical Note
moderateAllopurinol + Methyclothiazide
"The risk of a hypersensitivity reaction to Methyclothiazide is increased when it is combined with Allopurinol."
Clinical Note
moderateAllopurinol: 1–2 hours; oxypurinol: 18–30 hours (prolonged in renal impairment).
Allopurinol: 1-2 h; Oxypurinol: 18-30 h (prolonged in renal impairment, up to 7 days in severe CKD)
Renal: ~76% as unchanged drug and metabolites; oxypurinol (active metabolite) is primarily excreted renally. Biliary/fecal: minor, <5%.
Renal: ~70% (30% as allopurinol, 40% as oxypurinol); fecal: ~20%; biliary: minor (<5%)
Category C
Category C
Xanthine Oxidase Inhibitor
Xanthine Oxidase Inhibitor
Allopurinol + Hydroflumethiazide
"The risk of a hypersensitivity reaction to Hydroflumethiazide is increased when it is combined with Allopurinol."